Previous 10 | Next 10 |
La Jolla Pharmaceutical Company ( LJPC +14.5% ) is up on modest volume in early trade on the heels of positive interim dat a from a Phase 2 clinical trial evaluating LJPC-401 (synthetic human hepcidin) in patients with hereditary hemochromatosis , a disorder caused by the excessive abs...
- Treatment with LJPC-401 Resulted in Statistically Significant Reduction in Change in Transferrin Saturation (TSAT), the Primary Efficacy Endpoint of the Study, and Frequency of Phlebotomies, a Key Secondary Efficacy Endpoint of the Study - SAN DIEGO, June 06, 2019 (GLOBE NEWSWIRE)...
La Jolla Pharmaceutical (NASDAQ: LJPC ): Q1 GAAP EPS of -$1.17 beats by $0.28 . More news on: La Jolla Pharmaceutical Company, Earnings news and commentary, Healthcare stocks news, , Read more ...
SAN DIEGO, May 06, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today announc...
The FDA designates La Jolla Pharmaceutical's (NASDAQ: LJPC ) LJPC-0118 a Breakthrough Therapy (BTD) for the treatment of severe malaria. More news on: La Jolla Pharmaceutical Company, Healthcare stocks news, Stocks on the move, Read more ...
-Designation offers potential for expedited development and review, and highlights the urgent need for additional treatment options for patients suffering from severe malaria- - NDA Planned for LJPC-0118 for Fourth Quarter of 2019 - SAN DIEGO, April 24, 2019 (GLOBE NEWSWIRE) -- ...
SAN DIEGO, March 11, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today annou...
SAN DIEGO, March 07, 2019 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company (Nasdaq: LJPC), a leader in the discovery, development and commercialization of innovative therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases, today annou...
La Jolla Pharmaceutical Company (LJPC) Q4 2018 Results Conference Call March 04, 2019 04:30 PM ET Company Participants Sandra Vedrick - Director of Investor Relations and Human Resources George Tidmarsh - President and Chief Executive Officer Dennis Mulroy - Chief Financial Offic...
La Jolla Pharmaceutical (NASDAQ: LJPC ) Q4 results highlights: More news on: La Jolla Pharmaceutical Co., Healthcare stocks news, Earnings news and commentary, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
La Jolla Pharmaceutical Company Company Name:
LJPC Stock Symbol:
NASDAQ Market:
La Jolla Pharmaceutical Company Website:
Innoviva, Inc. (Nasdaq: INVA) (“Innoviva”), a diversified holding company with a portfolio of royalties and a growing portfolio of innovative healthcare assets, today announced that its tender offer to purchase any and all issued and outstanding shares of common stock of L...
The biotech investment sector has always been its own market, very distinct from other sectors. So it was no surprise that when most sectors turned slowly upward after the pandemic-inspired crash, Biotech (XBI) rose 164%, exceeding the overall market (SPY) performance by triple digits. Then, a...